Clazakizumab vs placebo or usual care
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Clazakizumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 0.69 [0.46, 1.04]2 studies · 169 participantsLow